Blocking IL-6 with tocilizumab (anti-IL-6 receptor (IL-6R) monoclonal antibody) can inhibit IgD-CD27- memory B cells and significantly improve the clinical symptoms of RA patients (34, 35). The gene discussed is CD27; the disease is rheumatoid arthritis.